HAE: Haemonetics Corp Price to Sales

Symbol and logo of brand Haemonetics Corp (HAE)

Haemonetics Corporation (HAE) maintains a leading position in the blood processing niche, leveraging patent protection and stringent government regulation. The current P/S multiple on the GURU.Markets daily chart reflects the valuation trend, where 4.00 is the current value of the indicator. Stable management has successfully diversified the device portfolio, while Christopher Simon's strategy to implement high-margin plasmapheresis technologies ensures profitability growth.

HAE (Haemonetics) P/S Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Haemonetics Corp. (HAE)

- market price and analyst price targets:
Stock Quotes haemonetics.com|HAE - Analyst Consensus Forecast
- market capitalization information:
Market Value Haemonetics Corp.|HAE - Enterprise Value
- shareholders' equity book value data:
Equity per Share Haemonetics|HAE - Book Capitalization|Market Capitalization to Book Value haemonetics.com|HAE - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Haemonetics Corporation|HAE - Long-Term Debt to Capital|Short-Term Debt to Capital Haemonetics Company|HAE - Company Debts|Debt to Book Capitalization Ratio Haemonetics Corp.|HAE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Haemonetics|Immediate Liquidity haemonetics.com
- net income and valuation multiples indicators:
HAE - Company Net Income|Projected Net Profit Haemonetics Corporation|HAE - Price to Earnings Ratio|Forward P/E Multiple Haemonetics Corp|HAE - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Haemonetics Corp.|HAE - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Haemonetics|HAE - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months haemonetics.com|HAE - Earnings growth in current year|Expected net earnings per share growth next year Haemonetics Corporation
- issuer revenue and sales details:
HAE - Company Revenue|Company Revenue Forecast haemonetics.com|HAE - Market Cap to Revenue|Price to Expected Revenue Ratio Haemonetics Corp.
Fundamental company analysis:haemonetics.com HAE
Original product of Haemonetics Corp.

The investment appeal of Haemonetics Corporation (HAE) is based on its status as a global technological leader in transfusion medicine and the high level of trust it maintains with medical centers. By analyzing the price-to-sales multiple on the GURU.Markets platform, an investor compares the business's market value with its annual revenue, allowing for an objective assessment of whether the asset is overvalued relative to the company's actual cash flows.

Who Haemonetics Corporation competes with

Market Cap to Revenue dexcom.com DXCM|P/S Multiple PEN (Penumbra)|Novanta Inc (NOVT) - Price to Sales|Inspire Sleep - P/S Multiple|PRCT (Procept) - Market Cap to Revenue Ratio|CNMD: P/S Multiple|PLSE - Price-to-Revenue Coefficient|INMD (InMode) - P/S Multiple|Market Cap to Revenue Picard Medical Corp (PMI)|P/S Multiple SRDX|P/S Multiple Eversense (SENS)|Price-to-Revenue Ratio NeuroPace, Inc. NPCE|Tactile Systems Technology, Inc. - Price-to-Revenue Ratio|SNWV: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OM (Outset Medical Inc)|ELMD: P/S Multiple|Price to Sales LENSAR Inc (LNSR)|Price-to-Revenue Ratio AVITA Medical, Inc.|PROF - Price-to-Revenue Multiple|Market Cap to Revenue BDMD (Baird Medical Investment)|P/S Multiple edap-tms.com (EDAP)|P/S Multiple APYX (Apyx Medical Corporation)|Price-to-Revenue Coefficient IceCure Medical Ltd. (ICCM)|LUNG - Price-to-Revenue Ratio|Price-to-Sales Ratio TELA|cytosorbents.com (CTSO) - Price-to-Revenue Ratio|Market Cap to Revenue Sensus Healthcare Inc|ZYXI (Zynex Inc) - P/S Multiple|Price to Sales electroCore Medical ECOR|Price-to-Revenue Ratio Vicarious Surgical Inc. (RBOT)|inspira-technologies.com - Market Cap to Revenue Ratio|SeaStar Medical - Market Cap to Revenue|Market Cap to Sales Volume IRIX (IRIDEX Corp)|Intelligent Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio XAIR (Beyond Air, Inc.)|PFSA: P/S Multiple|STRATA Skin Sciences, Inc. (SSKN) - P/S Multiple|GCTK (GlucoTrack, Inc.) - P/S Multiple|Price to Sales nanovibronix.com NAOV|Price-to-Revenue Ratio Venus Concept Corp (VERO)|Market Cap to Revenue Nuwellis Corp NUWE|Price-to-Revenue Ratio Aethlon Medical AEMD|Asensus Surgical Inc (ASXC) - Price to Sales|AVGR - Price-to-Revenue Ratio|BSGM (BioSig) - Market Cap to Revenue Ratio|CUTR: P/S Multiple|Price to Sales Know Labs Corporation (KNW)|Market Cap to Revenue NARI|NVRO (nevro.com) - Market Cap to Sales Volume|P/S Multiple RSLS|Price-to-Revenue Coefficient Silk Road Medical, Inc.